Safety and Efficacy of Abatacept in IgG4-Related Disease

Summary

This is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study. Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks).

Timeline

Start

2018-11-13

Primary completion

2020-04-10

Completion

2020-11-10

Drugs

Indications